Cureus

Review began 01/09/2022 Review ended 01/12/2022 Published 01/16/2022

#### © Copyright 2022

Talwar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

# Pylephlebitis With Hepatic Abscess Complicating a Case of Acute Pancreatitis in a Young Male: Startling Complication of Intra-Abdominal Sepsis

Dhruv Talwar <sup>1</sup>, Sourya Acharya <sup>1</sup>, Samarth Shukla <sup>2</sup>, Sunil Kumar <sup>1</sup>, Akhilesh Annadatha <sup>1</sup>

1. Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Wardha, IND 2. Department of Pathology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Wardha, IND

Corresponding author: Sourya Acharya, souryaacharya74@gmail.com

## **Abstract**

The thrombophlebitis of the portal vein and or its hepatic branches accompanied with a positive blood culture is known as pylephlebitis, with the most common cause as sepsis. Liver abscess formation resulting from pylephlebitis is a rare but potentially lethal complication. We report a case of a 30-year-old male who presented with acute pain in the abdomen along with nausea and vomiting for two days with a history of alcohol dependence. Upon investigation, it was revealed to be a case of acute pancreatitis with hepatic abscess with superior mesenteric and portal vein thrombosis. The patient was managed conservatively with antibiotics and anticoagulants successfully. This case highlights the importance of keeping pylephlebitis with a hepatic abscess as a crucial potential complication of acute pancreatitis as its management promptly prevents mortality.

Categories: Internal Medicine, Gastroenterology Keywords: pylephlebitis, thrombosis, portal vein, hepatic abscess, acute pancreatitis

## Introduction

Waller described pylephlebitis as the source of liver abscess in the year 1846. Pylephlebitis (suppurative, infected portal vein thrombosis (PVT)) is rare to encounter but a dangerous complication arising out of intra-abdominal or pelvic infection and is often associated with significant morbidity as well as mortality [1]. Noncirrhotic and nonmalignant thrombosis of the portal vein has inconclusive etiology in about 25% of the cases. Pylephlebitis is the infective thrombosis of the portal vein, which was considered universally fatal in the pre-antibiotic era. With the emergence of modern imaging modalities and antibiotics, the outcome of pylephlebitis has improved significantly. Pylephlebitis can complicate any intra-abdominal or pelvic infection that affects the region drained by the portal vein. The most common intraabdominal infections to be associated with pylephlebitis are appendicitis and diverticulitis [2]. Most commonly pylephlebitis is associated with polymicrobial infections followed by monomicrobial infections with Streptococcus viridans, Bacteroides fragilis, as well as Escherichia coli [1].

Amongst the reported cases of pylephlebitis with liver abscess, pancreatitis is a rare cause, with only 5% of the reported cases having pancreatitis as the etiology [3]. Initially, pylephlebitis starts off as thrombophlebitis of veins draining the mesentery, which then spreads to the portal system and then the liver. Thrombosis of the mesenteric vein might result in ischemia and infarction of the mesentery as well as necrosis of the bowel. Risk factors that might increase the chances of pylephlebitis are hypercoagulable state, deficiency of clotting factors, smoking, history of abdominal surgical procedure, steroid use, coronary artery disease, prior history of crebrovascular episode, deep vein thrombosis and cirrhosis.

The major challenge in treating pylephlebitis remains non-specific presentation of the condition. Patients usually present with pain in the abdomen, malaise, fever and nausea [4].

The imaging modality of choice in pylephlebitis is computed tomography which shows filling defects in the portal vein. While suspecting the diagnosis of pylephlebitis empirical antibiotic coverage should be initiated including metronidazole, gentamicin, piperacillin, ceftizoxime, imipenem, and ampicillin [5], which can be modified later on the basis of culture reports and treatment can be extended up to four to six weeks.

## **Case Presentation**

A 30-year-old male presented to the emergency department with a history of pain in the abdomen, fever, nausea and vomiting for two days. The patient had a history of alcohol abuse with the last intake four days back. His CAGE score was calculated to be 2. There was no history of hypertension, diabetes mellitus, coronary artery disease, deep vein thrombosis, cerebrovascular episode or any other chronic medical conditions in the past. On general examination, the patient was stable with a pulse of 82 beats per minute, blood pressure of 120/70 mm of hg in right arm supine position and SpO2 of 97% on room air. On systemic

#### How to cite this article

Talwar D, Acharya S, Shukla S, et al. (January 16, 2022) Pylephlebitis With Hepatic Abscess Complicating a Case of Acute Pancreatitis in a Young Male: Startling Complication of Intra-Abdominal Sepsis. Cureus 14(1): e21288. DOI 10.7759/cureus.21288

examination, the abdomen was soft with tenderness present in the epigastrium and the right hypochondrium and spleen was palpable. Heart sounds were normal, the chest was bilaterally clear and the patient was conscious and oriented. The patient was admitted for further evaluation and blood investigations were suggestive of acute pancreatitis with sepsis (Table 1). A contrast-enhanced computed tomography (CECT) of the abdomen was carried out, which was suggestive of acute pancreatitis with the portal and superior mesenteric vein thrombosis with hepatic abscess (Figure 1 and Figure 2). Ultrasonography was done by the interventional radiology team to assess the abscess for drainage and the abscess was found to be less than 5 cm in size and was advised to be managed conservatively. The patient was kept nil by mouth and started on empirical antibiotics (injectable metronidazole 100ml intravenous thrice a day and injectable piperacillin and tazobactam 4.45gm intravenous thrice a day) with anticoagulants (tablet nicoumalone 2mg once a day). During the course of the hospital stay, the patient improved clinically and amylase lipase decreased. The patient's blood culture was positive for Klebsiella pneumoniae. He was allowed an oral diet on day 5 of admission and was finally discharged in stable condition seven days after admission. The patient was continued on tablet ciprofloxacin 500mg once a day for six weeks after discharge. Anticoagulation was continued for a duration of six months post discharge.

Hemagiabin9.8 gm/dPlatelet court1.7 lak/dWhite blood cell count450/dKean Corpuscular Volume08 lnCreatinine2 mg/dSodium2 mg/dSodium3 fs mol/lPotassium4 mm/dTotal Protein4 mg/dAlbumin2 mg/dSolulin3 fs mol/lAlbumin3 fg mg/dSolulin3 fg mg/dAlbumin3 fg mg/dAlbumin3 fg mg/dSolulin3 fg mg/dAlbumin3 fg mg/dSolulin3 fg mg/dAlaine Anninotransferase8 units/lSolulin3 fg mg/dTotal Bilrubin3 fg mg/dTotal Bilrubin3 fg mg/dSoluligated Bilrubin1 fm gg/dSolur Lipase1 fg mg/dSolur Lipase1 fg mg/dSolur Lipase1 fg mg/dNart Mater1 fg mg/dSolur Lipase1 fg mg/dSolur Lipas	Lab Investigation	Measures Value
Plaleit court1.71 kk/dWhe blood court4500 (decourt)Mean Corpuscular Volume8.1Creatinine0.1Urea2.7 mg/dSolum2.7 mg/dPotassium4.4 mmo/dTotal Protein4.4 mmo/dAbumin2.7 mg/dGlobulin3.7 mg/dApartate Aminotransferase80 mts/dAkaine Phosphatase9.0 mts/dTotal Protein3.0 mts/dAution Apartate Aminotransferase9.0 mts/dAutiona Phosphatase3.0 mts/dConjugated Biltubin3.7 mg/dSorum Apartate Aminotransferation9.1 mts/dStart Apartate Aminotransferation9.0 mts/dAutione Phosphatase3.0 mts/dConjugated Biltubin3.0 mts/dSorum Apartate Aminotransferation9.0 mts/dSorum Apartate Aminotransferation9.0 mts/dSorum Apartate Aminotransferation9.0 mts/dAutine Phosphatase9.0 mts/dConjugated Biltubin1.2 mts/dSorum Apartate Aminotransferation1.2 mts/dSorum Apartate Aminotransferation9.0 mts/dAutine Apartate Aminotransferation1.2 mts/dAutine Apartate Aminotransferation	Hemoglobin	9.8 gm/dl
White blood cell count4500/dellMean Corpuscular Volume50 llCreatinine6.8 mg/dlUrea7 mg/dlSodum15 mmo/lPotassium16 mmo/lPotassium6.4 mmo/lTotal Protein6.4 mmo/lAlbumin7.7 mg/dlGlobulin3.7 mg/dlApartate Aminotransferase80 mults/Alaine Anapostate9.0 mults/Alaine Anapostate3.9 mults/Conjugated Bilrubin3.7 mg/dlConjugated Bilrubin3.7 mg/dlSerum Anylase3.0 mults/Serum Anylase1.9 mults/Informational constraints/1.9 mults/Informational constraints/1.9 mults/Serum Anylase1.9 mults/Informational constraints/1.9 mults/Infor	Platelet count	1.17 lakh/dl
Mean Corpuscular Volume80 flCreatinine0.8 mg/dlUrea27 mg/dlSodium10 mm/dlPotassium4.4 mm/dlTotal Protein6.4 gm/dlAlbumin27 gm/dlGlobulin7.9 mg/dlAlarine Aminotransferase80 mits/Alarine Phosphatas30 JU/lTotal Billrubin3.7 mg/dlTotal Billrubin3.7 mg/dlConjugated Billrubin3.1 mg/dlSerum Amylase6.9 mits/Serum Amylase6.9 mits/Porthormbintme1.4 mg/dlPorthormbintme1.9 mits/Altrine Ational protection1.9 mits/Serum Amylase6.9 mits/Serum Amylase6.9 mits/Porthormbintme1.9 mits/Altri Ational protection1.9 mits/Altri Ational protection1.9 mits/Serum Amylase1.9 mits/Porthormbintme1.9 mits/Altri Ational protection1.9 mits/<	White blood cell count	14500/dl
Creatinine0.8 mg/dlUrea7 mg/dlSodium35 mmo/dlPotassium4.4 mmo/dlTotal Protein4.9 mg/dlAlbumin2.7 gm/dlGlobulin3.7 gm/dlAspatate Aminotransferase80 mits/lAlkine Phosphatase39 U/lTotal Bilrubin1.9 mg/dlCojugated Bilrubin3.9 mg/dlSum Amyase9.0 mg/dlSum Amyase1.9 mg/dlSerum Amyase1.9 mg/dlSerum Amyase1.9 mg/dlNet International Internationa	Mean Corpuscular Volume	80 fl
Ura27 mg/dSolum35 mmg/dPotassium44 mmg/dTota Protein44 mmg/dAbumin27 gm/dGlobulin27 gm/dGhobulin37 gm/dApata Aminotransferase80 mits/dAlaine Phosphatase39 U/dTota Billinulin31 gm/dConjugated Bilinubin31 gm/dSexum Anyase61 gm/dSexum Anyase14 gm/dSexum Anyase12 gm/dPotrombin Image12 gm/dAnya Anyase12 gm/dSexum Anyase12 gm/dAnya Anyase12 gm/d<	Creatinine	0.8 mg/dl
Sodium135 mm/lPotassium4.4 mm/lTotal Protein6.4 gm/dAlumin2.7 gm/dGlobulin3.7 gm/dAspartate Aminotransferase88 units/Alanine Aminotransferase89 units/Alatine Phosphatase3.9 U/lTotal Bilirubin3.7 mg/dConjugated Bilirubin3.7 mg/dSeum Amylase9.1 mg/dSeum Amylase6149 units/Inconjugated Bilirubin1.29Nat Interstorm1.29Prothrombin time1.6Aptrt Activated partial thromboplastintime)8.4Aptrt Activated partial thromboplastintime)8.4Hepattis C VirusNegativeHV (Human Immunodeficiency Virus)Negative	Urea	27 mg/dl
Pdassim4.4 mm/dTotal Protein6.4 gm/dAlbumin6.4 gm/dAlbumin7.0 gm/dGlobulin8.0 mit/lApartate Aminotransferase80 mit/lAlatine Phosphatase30 mit/lTotal Bilrubin3.0 m/dTotal Bilrubin3.0 m/dConjugated Bilrubin3.0 m/dSerum Anylase6.0 mit/lSerum Anylase6.0 mit/lInternational mominger April1.4 mit/lNatification1.0 mit/lSerum Lipase6.0 mit/lInternational mominger April1.6 mit/lAptrt Activated partition three8.4 mit/lInternational Composition three8.4 mit/lInternational Composition three8.4 mit/lInternational protect April8.4 mit/lInternational protect April8.4 mit/lInternational protect April8.4 mit/lInternational protect April1.6 mit/lInternational prot	Sodium	135 mmol/l
Total Protein6.4 gm/dAlbumin2.7 gm/dGlobulin3.7 gm/dApartate Aminotransferase88 units/Alanine Aminotransferase89 units/Alaline Phosphatase309 U/lTotal Bilrubin3.7 mg/dConjugated Bilrubin1.4 mg/dUnconjugated Bilrubin679 units/Serum Anylase679 units/IR (International normalized ratio)1.29Prothrombin time1.8.6Apartate Antigen84.4Hepatitis B Surface AntigenNegativeHy (Human Immuodeficiency Virus)Negative	Potassium	4.4 mmol/l
Abumin27 gm/dlGlobulin37 gm/dlApartate Aminotransferase84 units/Alatine Aminotransferase89 units/Akaline Phosphatase339 U/ITotal Bilrubin37 m/dlConjugated Bilrubin14 m/dlUnconjugated Bilrubin14 m/dlSerum Anylase679 units/Serum Lipase129INR (International normalized ratio)1.29Arttry (Activated partial thromboplastin time)3.4Apartitis B Surface AntigenMagiaveHup (Human Immunodeficiency Virus)MagiaveHU (Human Immunodeficiency Virus)Magiave	Total Protein	6.4 gm/dl
Globulin3.7 gm/dlAspartate Aminotransferase88 units/lAlanine Aminotransferase89 units/lAlkaline Phosphatase339 U/lTotal Bilirubin3.7 mg/dlConjugated Bilirubin1.4 mg/dlUnconjugated Bilirubin2.3 mg/dlSerum Amylase679 units/lSerum Lipase1.49INR (International normalized ratio)1.29Prothrombin time8.4APTT (Activated partial thromboplastin time)8.4Hepatitis B Surface AntigenNegativeHIV (Human Immunodeficiency Virus)Negative	Albumin	2.7 gm/dl
Aspartate Aminotransferase88 units/lAlanine Aminotransferase89 units/lAkaline Phosphatase309 U/lTotal Bilirubin3.7 mg/dlConjugated Bilirubin1.4 mg/dlUnconjugated Bilirubin2.3 mg/dlSerum Amylase679 units/lSerum Lipase1.42International normalized ratio)1.29Prothrombin time3.8.4Apartitis B Surface AntigenNegativeHepatitis C VirusNegativeHU (Human Immunodeficiency Virus)Negative	Globulin	3.7 gm/dl
Alanine Aminotransferase89 units/lAklaine Phosphatase339 IU/lTotal Bilrubin3.7 mg/dlConjugated Bilrubin1.4 mg/dlUnconjugated Bilrubin2.3 mg/dlSerum Amylase679 units/lSerum Lipase1.49 units/lINR (International normalized ratio)1.29Prothrombin time8.4APTT (Activated partial thromboplastin time)8.4Hepatitis B Surface AntigenNegativeHU/ (Human Immunodeficiency Virus)Negative	Aspartate Aminotransferase	88 units/l
Akaline Phosphatase339 IU/Total Bilrubin3.7 mg/dlConjugated Bilrubin1.4 mg/dlUnconjugated Bilrubin2.3 mg/dlSerum Amylase679 units/Serum Lipase6149 units/INR (International mormalized ratio)1.29Prothrombin time8.6APTT (Activated partial thromboplastin time)8.4Hepatitis B Surface AntigenNegativeHU (Human Immunodeficiency Virus)Negative	Alanine Aminotransferase	89 units/l
Total Bilirubin3.7 mg/dlConjugated Bilirubin1.4 mg/dlUnconjugated Bilirubin2.3 mg/dlSerum Amylase679 units/lSerum Lipase6149 units/lINR (International normalized ratio)1.29Prothrombin time18.6APTT (Activated partial thromboplastin time)38.4Hepatitis B Surface AntigenNegativeHUV (Human Immunodeficiency Virus)Negative	Alkaline Phosphatase	339 IU/I
Conjugated Bilirubin1.4 mg/dlUnconjugated Bilirubin2.3 mg/dlSerum Amylase679 units/lSerum Lipase6149 units/lINR (International normalized ratio)1.29Prothrombin time18.6APTT (Activated partial thromboplastin time)38.4Hepatitis B Surface AntigenNegativeHUV (Human Immunodeficiency Virus)Negative	Total Bilirubin	3.7 mg/dl
Unconjugated Bilirubin2.3 mg/dlSerum Amylase679 units/lSerum Lipase6149 units/lINR (International normalized ratio)1.29Prothrombin time18.6APTT (Activated partial thromboplastin time)38.4Hepatitis B Surface AntigenNegativeHuy (Human Immunodeficiency Virus)Negative	Conjugated Bilirubin	1.4 mg/dl
Serum Amylase679 units/lSerum Lipase6149 units/lINR (International normalized ratio)1.29Prothrombin time8.6APTT (Activated partial thromboplastin time)38.4Hepatitis B Surface AntigenNegativeHuy (Human Immunodeficiency Virus)Negative	Unconjugated Bilirubin	2.3 mg/dl
Serum Lipase6149 units/lINR (International normalized ratio)1.29Prothrombin time18.6APTT (Activated partial thromboplastin time)38.4Hepatitis B Surface AntigenNegativeHepatitis C VirusNegativeHIV (Human Immunodeficiency Virus)Negative	Serum Amylase	679 units/l
INR (International normalized ratio)1.29Prothrombin time18.6APTT (Activated partial thromboplastin time)38.4Hepatitis B Surface AntigenNegativeHepatitis C VirusNegativeHIV (Human Immunodeficiency Virus)Negative	Serum Lipase	6149 units/l
Prothrombin time18.6APTT (Activated partial thromboplastin time)38.4Hepatitis B Surface AntigenNegativeHepatitis C VirusNegativeHIV (Human Immunodeficiency Virus)Negative	INR (International normalized ratio)	1.29
APTT (Activated partial thromboplastin time) 38.4   Hepatitis B Surface Antigen Negative   Hepatitis C Virus Negative   HIV (Human Immunodeficiency Virus) Negative	Prothrombin time	18.6
Hepatitis B Surface Antigen Negative   Hepatitis C Virus Negative   HIV (Human Immunodeficiency Virus) Negative	APTT (Activated partial thromboplastin time)	38.4
Hepatitis C Virus Negative   HIV (Human Immunodeficiency Virus) Negative	Hepatitis B Surface Antigen	Negative
HIV (Human Immunodeficiency Virus) Negative	Hepatitis C Virus	Negative
	HIV (Human Immunodeficiency Virus)	Negative

## TABLE 1: Laboratory investigations of the case



FIGURE 1: Contrast-enhanced computed tomography of the abdomen showing thrombosis of the main portal vein



FIGURE 2: Contrast-enhanced computed tomography of the abdomen showing right subcapsular hepatic abscess

## Discussion

Pylephlebitis is the septic inflammation of the portal vein and or its hepatic branches. Initially, it starts as an infection of small veins dragging the territory of infection in the abdomen. The spread of this infection to larger veins ultimately leads to pylephlebitis, which can further lead to thrombosis of mesenteric veins (Figure 3). Presenting complaints most commonly remain fever and pain in the abdomen while malaise, diarrhea, anorexia, nausea and vomiting are also reported [6]. Jaundice can be a rare sign of an underlying hepatic abscess. This abscess can be visualized on imaging via computed tomography. Pylephlebitis manifests as enlargement and occlusion of the portal vein and its branches with intravascular thrombus formation. Cavernomatous transformation or periportal collaterals can develop in as few as 20 days following pylephlebitis. In our case, pylephlebitis further resulted in hepatic abscess formation, which can be seen as a cluster of small foci [7]. A pyogenic liver abscess occurs as a complication of hematogenous spread and therefore is multifocal as opposed to amoebic or other abscesses making the possibility of hematogenous spread of infection leading to hepatic abscess more likely in our case. During the early phase of abscess formation, the margins appear ill-defined with small non-enhancing cystic areas. Also, there is a heterogeneous enhancement of the liver parenchyma around the abscess. During the course of time, the abscess forms a well-circumscribed outline which has a thick enhancing rim in the periphery with fluid and debris lying internally [8]. The main differential diagnosis of portal vein thrombosis occurring with hepatic abscess is malignancy such as intrahepatic cholangiocarcinoma or hepatocellular carcinoma. Hepatocellular carcinoma is more common in a patient with other risk factors like hepatitis B or C or a patient with cirrhosis-hepatocellular carcinoma on imaging shows arterial enhancement with a delayed or portal washout. Intrahepatic cholangiocarcinoma shows arterial enhancement in the periphery, which is followed by an enhancement that is delayed progressive and centripetal. Hyperenhancement of intrahepatic cholangiocarcinoma, which is delayed, is thought to be due to the dense fibrous stroma of the tumor [9].



### FIGURE 3: Pathophysiology of liver abscess formation in pylephlebitis

In a study carried out by Baril et al., it was found that patients with pylephlebitis had associated hypercoagulability [10]. A total of 18 patients out of 44 enrolled patients had associated hypercoagulable states which can be due to clotting factor deficiency or associated neoplasm. Our patient was also started on anticoagulant and is presently doing well on follow-up.

In our case, the absence of any imaging feature of malignancy with a clinical picture of fever with pain in the abdomen confirmed on lab investigations as sepsis with acute pancreatitis was suggestive of an intraabdominal source of sepsis with pylephlebitis leading to hepatic abscess as the diagnosis rather than malignancy. Pylephlebitis results as hematogenous dissemination of intraabdominal sepsis from locations drained by the portal system or splanchnic system. The most common etiology of pylephlebitis are diverticulitis, acute appendicitis, pancreatitis, inflammatory bowel disease and gastroenteritis. In our case, pylephlebitis and liver abscess were a complication of acute pancreatitis. The common cause of mortality is sepsis or peritonitis or bowel ischemia and infarction.

## Conclusions

Pyogenic liver abscess occurring as a complication of pylephlebitis due to intra-abdominal infection from acute pancreatitis is a rare but potentially fatal phenomenon. The treating physicians, along with respective radiologists, should therefore be alert and aware of such important but rare complications presenting with nonspecific complaints and no significant physical findings in order to prevent mortality and morbidity.

## **Additional Information**

### Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

## References

1. Radovanovic N, Dumic I, Veselinovic M, et al.: Fusobacterium necrophorum subsp. necrophorum liver

abscess with pylephlebitis: an abdominal variant of Lemierre's syndrome. Case Rep Infect Dis. 2020, 2020:9237267. 10.1155/2020/9237267

- Hoffman HL, Partington PF, Desanctis AL: Pylephlebitis and liver abscess. Am J Surg. 1954, 88:411-416. 10.1016/0002-9610(54)90358-X
- Santosh D, Low G: Pylephlebitis with liver abscess secondary to chronic appendicitis: a radiological conundrum. J Clin Imaging Sci. 2016, 6:37. 10.4103/2156-7514.190894
- Choudhry AJ, Baghdadi YM, Amr MA, Alzghari MJ, Jenkins DH, Zielinski MD: Pylephlebitis: a review of 95 cases. J Gastrointest Surg. 2016, 20:656-661. 10.1007/s11605-015-2875-3
- Wong K, Weisman DS, Patrice KA: Pylephlebitis: a rare complication of an intra-abdominal infection. J Community Hosp Intern Med Perspect. 2013, 3:10.3402/jchimp.v3i2.20732
- Plemmons RM, Dooley DP, Longfield RN: Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Clin Infect Dis. 1995, 21:1114-1120. 10.1093/clinids/21.5.1114
- De Gaetano AM, Lafortune M, Patriquin H, De Franco A, Aubin B, Paradis K: Cavernous transformation of the portal vein: patterns of intrahepatic and splanchnic collateral circulation detected with Doppler sonography. AJR Am J Roentgenol. 1995, 165:1151-1155. 10.2214/ajr.165.5.7572494
- Kawamoto S, Soyer PA, Fishman EK, Bluemke DA: Nonneoplastic liver disease: evaluation with CT and MR imaging. Radiographics. 1998, 18:827-848. 10.1148/radiographics.18.4.9672968
- Kim JW, Shin SS, Heo SH, Lim HS, Hur YH, Kim JH: Hepatic abscess mimicking hepatocellular carcinoma in a patient with alcoholic liver disease. Clin Mol Hepatol. 2013, 19:431-434. 10.3350/cmh.2013.19.4.431
- Baril N, Wren S, Radin R, Ralls P, Stain S: The role of anticoagulation in pylephlebitis . Am J Surg. 1996, 172:449-453. 10.1016/S0002-9610(96)00220-6